不同前列腺癌组特异性lncrna、mirna和mrna的评价。

IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY
Bioimpacts Pub Date : 2025-01-26 eCollection Date: 2025-01-01 DOI:10.34172/bi.30510
Gelareh Vahabzadeh, Amirreza Pashapour-Yeganeh, Maryam Eini, Morad Roudbaraki, Ebrahim Esmati, Amirhoushang Poorkhani, Solmaz Khalighfard, Ali Mohammad Alizadeh
{"title":"不同前列腺癌组特异性lncrna、mirna和mrna的评价。","authors":"Gelareh Vahabzadeh, Amirreza Pashapour-Yeganeh, Maryam Eini, Morad Roudbaraki, Ebrahim Esmati, Amirhoushang Poorkhani, Solmaz Khalighfard, Ali Mohammad Alizadeh","doi":"10.34172/bi.30510","DOIUrl":null,"url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>LncRNAs interact with miRNAs and mRNAs that can have a special expression pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer (PC).</p><p><strong>Methods: </strong>The mRNAs with significant expression differences were first analyzed using the GEO and TCGA databases. The lncRNAs and miRNAs were then identified in the miRWalk2, miRmap, OncomiR, miRGator 3.0, miRCancerDB, LncRNA2target, TANRIC, LncRNADisease, Lnc2Cancer v3.0, and LncBase. Seventy subjects, including sixty PC patients classified as local, locally advanced, biochemical relapse, metastatic, and benign groups, as well as ten normal individuals, were then included. Finally, real-time PCR determined the expression of the candidate biomarkers.</p><p><strong>Results: </strong>The bioinformatics analysis detected candidate 6 miRNAs, 6 lncRNAs, and 6 mRNAs in different groups of PC patients. Unlike the significant decrease in candidate tumor suppressors, the expression levels of specific onco-lncRNA, onco-miRNA, and oncogenes exhibited a substantial increase in different groups of the patients compared to the normal group. The expression of lncRNAs, including LINC01128 (<i>P</i>=0.0182), LINC02246 (<i>P</i><0.0001), and LINC02288 (<i>P</i><0.0001), LINC00857 (<i>P</i><0.0001), GNAS-AS1 (<i>P</i><0.0001), and LINC02371 (<i>P</i><0.0001), the expression of miRNAs, including miR-217 (<i>P</i><0.0001), miR-375 (<i>P</i><0.0001), miR-203a (<i>P</i><0.0001), miR-876 (<i>P</i>=0.0046), miR-27b (<i>P</i><0.0001), and miR-152 (<i>P</i><0.0001), and the expression of oncogenes, including ST14 (<i>P</i><0.0001), CD24 (<i>P</i><0.0001), CDH1 (<i>P</i><0.0001), DSC2 (<i>P</i><0.0001), TGFB3 (<i>P</i><0.0001), and MYL2 (<i>P</i>=0.0186) had significant changes at different groups of PC patients.</p><p><strong>Conclusion: </strong>Our results identified promising biomarkers that play a role in specific groups of prostate cancer patients. Detecting specific biomarkers may be an effective strategy for different groups of PC patients.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30510"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008508/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer.\",\"authors\":\"Gelareh Vahabzadeh, Amirreza Pashapour-Yeganeh, Maryam Eini, Morad Roudbaraki, Ebrahim Esmati, Amirhoushang Poorkhani, Solmaz Khalighfard, Ali Mohammad Alizadeh\",\"doi\":\"10.34172/bi.30510\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p></p><p><strong>Introduction: </strong>LncRNAs interact with miRNAs and mRNAs that can have a special expression pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer (PC).</p><p><strong>Methods: </strong>The mRNAs with significant expression differences were first analyzed using the GEO and TCGA databases. The lncRNAs and miRNAs were then identified in the miRWalk2, miRmap, OncomiR, miRGator 3.0, miRCancerDB, LncRNA2target, TANRIC, LncRNADisease, Lnc2Cancer v3.0, and LncBase. Seventy subjects, including sixty PC patients classified as local, locally advanced, biochemical relapse, metastatic, and benign groups, as well as ten normal individuals, were then included. Finally, real-time PCR determined the expression of the candidate biomarkers.</p><p><strong>Results: </strong>The bioinformatics analysis detected candidate 6 miRNAs, 6 lncRNAs, and 6 mRNAs in different groups of PC patients. Unlike the significant decrease in candidate tumor suppressors, the expression levels of specific onco-lncRNA, onco-miRNA, and oncogenes exhibited a substantial increase in different groups of the patients compared to the normal group. The expression of lncRNAs, including LINC01128 (<i>P</i>=0.0182), LINC02246 (<i>P</i><0.0001), and LINC02288 (<i>P</i><0.0001), LINC00857 (<i>P</i><0.0001), GNAS-AS1 (<i>P</i><0.0001), and LINC02371 (<i>P</i><0.0001), the expression of miRNAs, including miR-217 (<i>P</i><0.0001), miR-375 (<i>P</i><0.0001), miR-203a (<i>P</i><0.0001), miR-876 (<i>P</i>=0.0046), miR-27b (<i>P</i><0.0001), and miR-152 (<i>P</i><0.0001), and the expression of oncogenes, including ST14 (<i>P</i><0.0001), CD24 (<i>P</i><0.0001), CDH1 (<i>P</i><0.0001), DSC2 (<i>P</i><0.0001), TGFB3 (<i>P</i><0.0001), and MYL2 (<i>P</i>=0.0186) had significant changes at different groups of PC patients.</p><p><strong>Conclusion: </strong>Our results identified promising biomarkers that play a role in specific groups of prostate cancer patients. Detecting specific biomarkers may be an effective strategy for different groups of PC patients.</p>\",\"PeriodicalId\":48614,\"journal\":{\"name\":\"Bioimpacts\",\"volume\":\"15 \",\"pages\":\"30510\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008508/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioimpacts\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.34172/bi.30510\",\"RegionNum\":4,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioimpacts","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.34172/bi.30510","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

简介:LncRNAs与在特定细胞类型中具有特殊表达模式的mirna和mrna相互作用。我们研究了不同前列腺癌(PC)组中特异性的lncrna、mirna和mrna。方法:首先使用GEO和TCGA数据库分析具有显著表达差异的mrna。然后在miRWalk2、miRmap、OncomiR、miRGator 3.0、miRCancerDB、LncRNA2target、TANRIC、LncRNADisease、lncr2cancer v3.0和lncrbase中鉴定lncrna和mirna。70名受试者,包括60名PC患者,分为局部、局部晚期、生化复发、转移和良性组,以及10名正常人。最后,real-time PCR检测候选生物标志物的表达。结果:生物信息学分析在不同组PC患者中检测到候选mirna 6个、lncrna 6个、mrna 6个。与候选肿瘤抑制因子的显著下降不同,与正常组相比,不同组患者特异性的onco-lncRNA、onco-miRNA和癌基因的表达水平均显著升高。LINC01128 (P=0.0182)、LINC02246 (PPPPPPPPP=0.0046)、miR-27b (PPPPPPPP=0.0186)等lncrna的表达在不同组PC患者中均有显著变化。结论:我们的研究结果确定了在特定前列腺癌患者群体中发挥作用的有希望的生物标志物。检测特定的生物标志物可能是不同群体PC患者的有效策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer.

Introduction: LncRNAs interact with miRNAs and mRNAs that can have a special expression pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer (PC).

Methods: The mRNAs with significant expression differences were first analyzed using the GEO and TCGA databases. The lncRNAs and miRNAs were then identified in the miRWalk2, miRmap, OncomiR, miRGator 3.0, miRCancerDB, LncRNA2target, TANRIC, LncRNADisease, Lnc2Cancer v3.0, and LncBase. Seventy subjects, including sixty PC patients classified as local, locally advanced, biochemical relapse, metastatic, and benign groups, as well as ten normal individuals, were then included. Finally, real-time PCR determined the expression of the candidate biomarkers.

Results: The bioinformatics analysis detected candidate 6 miRNAs, 6 lncRNAs, and 6 mRNAs in different groups of PC patients. Unlike the significant decrease in candidate tumor suppressors, the expression levels of specific onco-lncRNA, onco-miRNA, and oncogenes exhibited a substantial increase in different groups of the patients compared to the normal group. The expression of lncRNAs, including LINC01128 (P=0.0182), LINC02246 (P<0.0001), and LINC02288 (P<0.0001), LINC00857 (P<0.0001), GNAS-AS1 (P<0.0001), and LINC02371 (P<0.0001), the expression of miRNAs, including miR-217 (P<0.0001), miR-375 (P<0.0001), miR-203a (P<0.0001), miR-876 (P=0.0046), miR-27b (P<0.0001), and miR-152 (P<0.0001), and the expression of oncogenes, including ST14 (P<0.0001), CD24 (P<0.0001), CDH1 (P<0.0001), DSC2 (P<0.0001), TGFB3 (P<0.0001), and MYL2 (P=0.0186) had significant changes at different groups of PC patients.

Conclusion: Our results identified promising biomarkers that play a role in specific groups of prostate cancer patients. Detecting specific biomarkers may be an effective strategy for different groups of PC patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bioimpacts
Bioimpacts Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
4.80
自引率
7.70%
发文量
36
审稿时长
5 weeks
期刊介绍: BioImpacts (BI) is a peer-reviewed multidisciplinary international journal, covering original research articles, reviews, commentaries, hypotheses, methodologies, and visions/reflections dealing with all aspects of biological and biomedical researches at molecular, cellular, functional and translational dimensions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信